［1］Torre LA，Bray F，Siegel RL，et al.Global cancer statistics，2012［J］.CA Cancer J Clin，2015，65(2)：87-108.
［2］Sharma P，Allison JP.The future of immune checkpoint therapy［J］.Science，2015，348(6230)：56-61.
［3］Gubin MM，Zhang X，Schuster H，et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens［J］.Nature，2014，515(7528)：577-581.
［4］Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy［J］.Nat Rev Cancer，2012，12(4)：252-264.
［5］Postow MA，Callahan MK，Wolchok JD.Immune checkpoint blockade in cancer therapy［J］.J Clin Oncol，2015，33(17)：1974-1982.
［6］La-Beck NM，Jean GW，Huynh C，et al.Immune checkpoint inhibitors：New insights and current place in cancer therapy［J］.Pharmacotherapy，2015，35(10)：963-976.
［7］Xia B，Herbst RS.Immune checkpoint therapy for non-small-cell lung cancer：An update［J］.Immunotherapy，2016，8(3)：279-298.
［8］Kroemer G，Galluzzi L.Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark［J］.Oncoimmunology，2015，4(7)：e1058037.
［9］Sharma P，Allison JP.Immune checkpoint targeting in cancer therapy：toward combination strategies with curative potential［J］.Cell，2015，161(2)：205-214.
［10］Remon J，Pardo N，Martinez-Martí A，et al.Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients：Current status and future approaches［J］.Lung Cancer，2017(106)：70-75.
［11］Curran MA，Montalvo W，Yagita H，et al.PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors［J］.Proc Natl Acad Sci USA，2010，107(9)：4275-4280.
［12］Remon J，Pardo N，Martinez-Martí A，et al.Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients：Current status and future approaches［J］.Lung Cancer，2017(106)：70-75.
［13］Rizvi NA，Hellmann MD，Snyder A，et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］.Science，2015，348(6230)：124-128.
［14］Das R，Verma R，Sznol M，et al.Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo［J］.J Immunol，2015，194(3)：950-959.
［15］Hammers HJ，Plimack ER，Infante JR，et al.Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma：The checkmate 016 study［J］.J Clin Oncol，2017，35(34)：3851-3858.
［16］Hellmann MD，Rizvi NA，Goldman JW，et al.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012)：Results of an open-label，phase 1，multicohort study［J］.Lancet Oncol，2017，18(1)：31-41.
［17］Antonia SJ，López-Martin JA，Bendell J，et al.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032)：A multicentre，open-label，phase 1/2 trial［J］.Lancet Oncol，2016，17(7)：883-895.
［18］Hodi FS，Chesney J，Pavlick AC，et al.Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma：2-year overall survival outcomes in a multicentre，randomised，controlled，phase 2 trial［J］.Lancet Oncol，2016，17(11)：1558-1568.
［19］Larkin J，Hodi FS，Wolchok JD.Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma［J］.N Engl J Med，2015，373(13)：1270-1271.
［20］Postow MA，Chesney J，Pavlick AC，et al.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma［J］.N Engl J Med，2015，372(21)：2006-2017.
［21］Liu WM，Fowler DW，Smith P，et al.Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses［J］.Br J Cancer，2010，102(1)：115-123.
［22］Peng J，Hamanishi J，Matsumura N，et al.Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κb to foster an immunosuppressive tumor microenvironment in ovarian cancer［J］.Cancer Res，2015，75(23)：5034-5045.
［23］Jure-Kunkel M，Masters G，Girit E，et al.Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models［J］.Cancer Immunol Immunother，2013，62(9)：1533-1545.
［24］Manukian G，Bar-Ad V，Lu B，et al.Combining radiation and immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma［J］.Front Oncol，2019(9)：122.
［25］Solanki AA，Bossi A，Efstathiou JA，et al.Combining immunotherapy with radiotherapy for the treatment of genitourinary malignancies［J］.Eur Urol Oncol，2019，2(1)：79-87.
［26］Kanda S，Goto K，Shiraishi H，et al.Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer：a four arms phase Ib study［J］.Ann Oncol，2016，27(12)：2242-2250.
［27］Rosenberg JE，Hoffman-Censits J，Powles T，et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy：A single-arm，multicentre，phase 2 trial［J］.Lancet，2016，387(10031)：1909-1920.
［28］Cyprian FS，Akhtar S，Gatalica Z，et al.Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy：A new clinical paradigm in the treatment of triple-negative breast cancer［J］.Bosn J Basic Med Sci，2019:27.
［29］Pacheco JM，Camidge DR，Doebele RC，et al.A changing of the guard：Immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer［J］.Front Oncol，2019(9)：195.
［30］Langer CJ，Gadgeel SM，Borghaei H，et al.Carboplatin and pemetrexed with or without pembrolizumab for advanced，non-squamous non-small-cell lung cancer：A randomised，phase 2 cohort of the open-label KEYNOTE-021 study［J］.Lancet Oncol，2016，17(11)：1497-1508.
［31］Reck M，Bondarenko I，Luft A，et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer：Results from a randomized，double-blind，multicenter phase 2 trial［J］.Ann Oncol，2013，24(1)：75-83.
［32］Reck M，Luft A，Szczesna A，et al.Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer［J］.J Clin Oncol，2016，34(31)：3740-3748.
［33］Abdel-Rahman O，Helbling D，Schmidt J，et al.Treatment-associated fatigue in cancer patients treated with immune checkpoint inhibitors；a systematic review and meta-analysis［J］.Clin Oncol(R Coll Radiol)，2016，28(10)：e127-138.
［34］Abdel-Rahman O，Helbling D，Schmidt J，et al.Treatment-related death in cancer patients treated with immune checkpoint inhibitors：a systematic review and meta-analysis［J］.Clin Oncol(R Coll Radiol)，2017，29(4)：218-230.
［35］Wu Y，Shi H，Jiang M，et al.The clinical value of combination of immune checkpoint inhibitors in cancer patients：A meta-analysis of efficacy and safety［J］.Int J Cancer，2017，141(12)：2562-2570.
［36］Govindan R，Szczesna A，Ahn MJ，et al.Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer［J］.J Clin Oncol，2017，35(30)：3449-3457.
［37］Antonia SJ，Villegas A，Daniel D，et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer［J］.N Engl J Med，2017，377(20)：1919-1929.
［38］Lynch TJ，Bondarenko I，Luft A，et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer：Results from a randomized，double-blind，multicenter phase II study［J］.J Clin Oncol，2012，30(17)：2046-2054.
［39］Robert C，Thomas L，Bondarenko I，et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］.N Engl J Med，2011，364(26)：2517-2526.
［40］Weber J，Hamid O，Amin A，et al.Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma［J］.Cancer Immun，2013(13)：7.
［41］Hersh EM，O'Day SJ，Powderly J，et al.A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-nave patients with advanced melanoma［J］.Invest New Drugs，2011，29(3)：489-498.
［42］Antonia SJ，López-Martin JA，Bendell J，et al.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer(CheckMate 032)：A multicentre，open-label，phase 1/2 trial［J］.Lancet Oncol，2016，17(7)：883-895.
［43］Wolchok JD，Chiarion-Sileni V，Gonzalez R，et al.Overall survival with combined nivolumab and ipilimumab in advanced melanoma［J］.N Engl J Med，2017，377(14)：1345-1356.
［44］Chesney J，Puzanov I，Collichio F，et al.Randomized，open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced，unresectable melanoma［J］.J Clin Oncol，2018，36(17)：1658-1667.
［45］Govindan R，Szczesna A，Ahn MJ，et al.Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer［J］.J Clin Oncol，2017，35(30)：3449-3457.
［46］Hodi FS，O'Day SJ，McDermott DF，et al.Improved survival with ipilimumab in patients with metastatic melanoma［J］.N Engl J Med，2010，363(8)：711-723.
［47］Hodi FS，Lee S，McDermott DF，et al.Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma：a randomized clinical trial［J］.Jama，2014，312(17)：1744-1753.
［48］Theurich S，Rothschild SI，Hoffmann M，et al.Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma［J］.Cancer Immunol Res，2016，4(9)：744-754.
［49］Kwon ED，Drake CG，Scher HI，et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy(CA184-043)：A multicentre，randomised，double-blind，phase 3 trial［J］.Lancet Oncol，2014，15(7)：700-712.
［50］Khair DO，Bax HJ，Mele S，et al.Combining immune checkpoint inhibitors：Established and emerging targets and strategies to improve outcomes in melanoma［J］.Front Immunol，2019(10)：453.